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The monitoring of lymphatic drainage is of great importance, particularly in the context of the 
early detection and diagnosis of several diseases. Existing methods of imaging and monitoring lymphatic 
drainage can be costly and require trained personnel, posing problems for at-home or point-of-care 
monitoring. Recently, an alternative approach has been proposed, consisting of using microneedles to 
deliver a near-infrared (NIR) fluorescent tattoo to the skin, which can be monitored with traditional 
laboratory-based fluorescence detectors. In this work, we present further development of this approach, 
using a specifically designed NIR-fluorescent probe and rational optimization of microneedle properties 
and the spatial location of the NIR dye within the microneedles. Moreover, we demonstrate that this 
method is compatible with a custom-made portable fluorescence measurement device and able to 
discriminate between drainage and lack of drainage in vivo in rats. 




The lymphatic system consists of a network of vessels and nodes that spread throughout the 
body, playing an essential role in tissue homeostasis, immune response, and dietary fat absorption in the 
intestine [1,2]. A variety of pathological conditions are associated with altered lymphatic function, 
including primary and secondary lymphedema [3,4], lipedema [5], venous insufficiencies [6], impaired 
wound healing [7], scleroderma [8], and psoriasis [9]. Among these, secondary lymphedema affects 
approximately 3 million people in the United States, and is characterized by an accumulation of 
interstitial fluid in the extremities due to impaired lymphatic drainage [3,4]. In the developed world, 
secondary lymphedema occurs most commonly as a complication of breast cancer treatment, primarily 
resulting from the operative excision of lymph nodes to limit potential metastasis [10,11]. Because of the 
significant impact to quality of life caused by this disorder, as well as the improved outcomes associated 
with rapid treatment, the early detection of secondary lymphedema is considered to be of critical 
importance [12]. 
In clinical practice, lymphedema is most often diagnosed based on clinical presentation, 
particularly changes in limb volume. While not part of routine diagnosis, medical imaging can be used to 
support initial clinical evaluation by providing a more quantitative assessment of lymphatic function. 
While lymphatic imaging techniques are less developed than those used for imaging the circulatory 
system, a variety of approaches are used, such as scintigraphy-based techniques (considered the gold-
standard) [13], and more rarely, magnetic resonance [14] and computed tomography [15]. However, there 
remains significant drawbacks associated with the cost and complexity of these imaging strategies, which 
has led to the development of a new, simple, and affordable technique, namely lymphatic imaging using 
near-infrared (NIR) tracers [16]. This technique offers high sensitivity and spatial resolution, owing to the 
minimal tissue auto-fluorescence observed at NIR wavelengths (>750 nm), which enables a minimally-
invasive visualization  of lymphatic vessels and assessment of their function [17]. This is notably limited 
to surface-level lymphatics, though NIR fluorescence does provide improved tissue penetration depth 
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relative to other fluorescence imaging techniques [18,19]. 
In addition to the detection of impaired lymphatic function, NIR fluorescence imaging has been 
studied extensively for the structural assessment of lymphatic vasculature [20-22]. In these initial studies, 
the most common NIR fluorescent dye used was indocyanine green (ICG) [23,24], a tricarbocyanine dye 
that can be excited around 780 nm, with peak fluorescence emission around 813 nm [25]. Despite its 
advantages relative to other methods of lymphatic imaging, the delivery of ICG remains a painful 
procedure, requiring subcutaneous or intradermal injection to reach lymphatically vascularized tissues. 
Additionally, it has been reported that intradermal injection can lead to a localized increase in interstitial 
pressure within the dermis, potentially increasing the rate of ICG drainage and interfering with 
measurements [26,27]. A proposed solution to this issue has been the delivery of ICG using microneedles 
(MNs) [28]. Consisting of miniaturized needles with lengths below 1 mm, often assembled into an array, 
MNs are long enough to pierce the skin’s outer barrier — the epidermis — but short enough to avoid 
activating pain-sensing neurons found deeper in the tissue [29,30].  While initially proposed for the 
delivery of therapeutics, in recent years MNs have been increasingly studied for their potential diagnostic 
applications [31]. In a previous study, dissolving polymeric MNs were shown in mice to be able to 
effectively deliver ICG across the stratum corneum, allowing the visualization of lymphatic vessels [28]. 
Soluble polymeric MNs offer several advantages over other described classes (e.g. solid metal MNs or 
hollow silicon MNs), due to their simple manufacturing process, easy disposal, and the ability to 
incorporate a fluorescent dye directly into the structure of the MNs, allowing release upon dissolution in 
the skin [32-34]. 
In numerous works on lymphatic imaging, the NIR dye selected was ICG, likely based on its 
FDA-approved status and long history of clinical use, dating to 1959 [35]. While it remains the only 
currently clinically approved NIR tracer, ICG poses several limitations for use in vivo including its rapid 
degradation, poor solubility (resulting in fluorescence quenching), and low quantum yield [25,36,37]. Of 
particular note is the increase in quantum yield displayed by ICG upon binding to proteins in vivo, which 
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could complicate rapid initial measurements of lymphatic drainage [38]. Further, studies have 
demonstrated that administration of ICG can result in acute impairment of lymphatic function, which 
could pose significant problems when using the dye to quantify lymphatic drainage [39,40].  Finally, as a 
small molecule, ICG has been previously shown to have limited selectivity for drainage via the lymphatic 
system and can also be drained through blood vessels, thus limiting the specificity and sensitivity of this 
imaging technique [41]. A potential solution to these issues lies in the use of PEGylated dye conjugates, 
which have been shown to promote selective lymphatic targeting in the context of drug delivery in vivo 
[42-44]. PEGylation increases the size of the dye molecule and has been shown to allow for greater 
lymphatic specificity; with the added benefit of improved solubility, due to the hydrophilic nature of the 
PEG polymer, which serves to mitigate the degradation and quenching observed with ICG [41,45]. This 
strategy has also been applied to other NIR dyes, which have subsequently displayed improved solubility, 
as well as much higher selectivity for drainage through lymphatic vessels following intradermal 
administration [41]. In particular, it was found that a 20 kDa PEG chain resulted in excellent selectivity 
for lymphatic drainage while remaining small enough to easily diffuse through the skin [41]. This 
behavior is well characterized, and such conjugates have been used for NIR lymphatic imaging in a 
variety of studies since their development [46-48]. However, these conjugates were still delivered through 
standard intradermal injection, necessitating trained personnel, generating sharp waste, and requiring that 
analysis be performed in a hospital setting; all of which are obstacles to the development of a home-based 
lymphedema monitoring system. 
Taking advantage on the minimally invasive nature of MNs, and the improved solubility and 
lymphatic selectivity of PEGylated NIR tracers, we investigated the design of a dissolving polymeric MN 
patch loaded with a PEG (20 kDa) conjugate of Cyanine 7.5 (Cy7.5), a NIR fluorescent probe. This MN 
patch was shown to be capable of delivering the PEGylated Cy7.5 tracer to the skin, creating a potential 
fluorescent medical MN tattoo for lymphedema monitoring. Through rational design, it was found that 
lymphatic drainage function could be reliably followed using in vivo mouse and rat models. Specifically, 
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it was determined that the length of the MNs, as well as the spatial location of the fluorescent tracer 
within the tips, is critical to limit the high levels of background signal occurring when the dye is not 
drained from the application site — an issue of great importance for the actual diagnostic potential of the 
procedure. Additionally, it was shown that this system could be paired with a portable detection 
technology, demonstrating the potential for simple, minimally-invasive, home-based monitoring of 
lymphatic drainage [49]. Importantly, we highlight the significance of MN properties, which have 
important implications for the transdermal delivery of other macromolecules through dissolving 
polymeric MN systems. 
3. Results and Discussion 
3.1. Synthesis and Characterization of Cy7.5-PEG 
In this study, Cyanine-7.5 (Cy7.5) was selected as the NIR dye candidate for quantifying 
lymphatic drainage, as an alternative to the previously-studied ICG. Cy7.5 was chosen based on the 
availability of a N-hydroxysuccinimide (NHS) ester of the dye, allowing for simple chemical 
functionalization, which was found to be difficult to accomplish with ICG. Displaying comparable 
excitation and emission wavelengths to ICG (λex = 788 nm, λem = 808 nm for Cy7.5; λex = 788 nm, λem = 
813 nm for ICG) this dye is similarly well-suited for in vivo imaging in terms of spectral properties. 
However, unconjugated Cy7.5 exhibits poor water solubility (potentially leading to aggregation and 
cellular uptake) [36,37], and as a small molecule, is susceptible to the same non-specific drainage 
observed with ICG after intradermal administration [28,49]. To address both of these issues, an activated 
NHS ester of Cy7.5 was conjugated through amine coupling to a 20 kDa PEG polymer, as this length of 
PEG was previously found to be optimal for selective lymphatic drainage (Figure 1A) [41]. As expected, 
the resulting conjugate (Cy7.5-PEG) displayed greatly increased solubility relative to free Cy7.5 (2 mM 
vs. 3 µM), and is known to be too large and hydrophilic to be taken up by dermal cells (Figure S1). 
Further, previous studies have shown that 20 kDa PEGylated dyes are large enough to be selectively drained 
through lymphatic vessels while remaining small enough to diffuse away from the delivery site in the 
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dermis when administered through intradermal injection [41-43]. The excitation and emission spectra of 
Cy7.5-PEG were also examined relative to the unconjugated Cy7.5-NHS ester and no difference was 
observed, highlighting that the fluorescence properties of the dye are retained after PEGylation (Figure 
1B). 
 
Figure 1. Synthesis and characterization of Cy7.5-PEG: A) Synthesis of Cy7.5-PEG; B) Excitation 
and emission spectra of Cy7.5 and Cy7.5-PEG. 
3.2. Preparation and Characterization of Dissolving Polymeric MNs 
While earlier studies utilized MNs composed of pure poly(N-vinylpyrrolidone) (Mw = 3,500 – 
7,000 Da) (PVP K-12), this polymer was found to require long drying times (> 3 days) and was 
associated with fluorophore degradation [28]. Further, it was observed that MNs prepared from PVP K-12 
alone were very hygroscopic and required delicate storage conditions to preserve their structure. To 
address this, MNs were prepared from a 1:1 mixture of PVP K-12 and poly(vinyl alcohol) (Mw = 10,000 
Da) (PVA) — both injectable polymers commonly used for dissolving MNs — using a solvent casting 
method in polydimethylsiloxane (PDMS) molds [50-53]. The resulting MNs were found to dry within 24 
– 48 hours under ambient conditions and produced sharp, uniform MNs, highlighting the suitability of the 
polymer blend. In addition to their physical properties, the biocompatibility of both polymers has been 
widely studied, demonstrating that both PVP and PVA, with molecular weights greater than or equal to 
those used in our study, undergo rapid renal excretion after injection and have not been found to 
bioaccumulate [54-56]. Under bright-field microscopy, the MNs appeared as a 15 × 15 array of square 
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pyramidal projections with average lengths of 479 ± 13 µm and widths of 248 ± 6 µm × 248 ± 6 µm at the 
base (Figure 2A). While the base dimensions of the MNs were in agreement with those of the PDMS 
molds (250 µm × 250 µm), the lengths were significantly shorter than the nominal lengths of the molds 
(600 µm) (Figure S2), likely due to water loss during the drying process, as previously described [57]. 
The classical solvent casting process allowed a dye to be dispersed throughout the solid structure of the 
MNs, including the tips and the backing layer. However, when using MNs for dermal delivery, only the 
tips dissolve and release their payload, meaning that any dye in the backing layer remains unused. More 
significantly, dye at the base of the MN tips would primarily be delivered to the stratum corneum and 
would thus not be drained from the skin, resulting in a high background signal and reducing the sensitivity 
of the system. This is consistent with observations from previous studies using dissolving polymeric 
MNs, where strong fluorescence was localized in the outermost regions of the skin after delivery of a 
fluorescent dye [33,34,58]. To resolve this limitation, the solvent casting method was modified to allow 
dye to be incorporated only in the tips of the MNs, with the backing layer composed of dye-free polymer, 
by adapting a previously described method [17]. Under fluorescence stereomicroscopy, Cy7.5-PEG 
fluorescence could be observed exclusively in the tips of the MNs, with no apparent diffusion into the 
backing layer (Figure 2B). The dye-containing MNs were also examined using scanning electron 
microscopy (SEM), which revealed smooth, sharp MNs with tip diameters below 10 µm, sufficient to 




Figure 2. Structure and properties of Cy7.5-PEG-containing polymeric MNs: A) Brightfield image 
of PVP/PVA (1:1) MNs with Cy7.5-PEG in the tips. Scale bar = 500 µm; B) Fluorescent image of 
Cy7.5-PEG localized within MN tips. Scale bar = 500 µm; C) SEM image of PVP/PVA MNs. Scale bar 
= 10 µm; D) Brightfield image of PDMS mold used to make MNs. Scale bar = 5 mm; E) Mechanical 
properties of PVP/PVA (1:1) MNs with increasing concentrations of PEG-NH2 (20 kDa), Mean  ± SD (n 
= 4); F) Effect of application time on delivery of Cy7.5-PEG to mouse skin ex vivo, Mean ± SD (n = 3); 
G) Fluorescence intensity of MNs containing ICG or Cy7.5-PEG, Mean ± SD (n = 8), p < 0.0001; H) 
Fluorescence intensity of ICG or Cy7.5-PEG MN tattoos, Mean ± SD (n =4), p ≤ 0.0005. 
To ensure that the strength of the MNs was sufficient to pierce the skin, even when large amounts 
of PEG were loaded, increasing concentrations of PEG-NH2 (20 kDa) were incorporated into the MNs 
and the compression force required to induce structural failure was measured. Ultimately, no significant 
relationship was observed between failure force and the concentration of PEG-NH2 (20 kDa), indicating 
that the concentrations of PEGylated dye used in our experiments did not negatively impact the 
mechanical properties of the MNs (Figure 2D). Collectively, the tested MNs displayed an average failure 
force of 9.6 ± 1.8 N, well above the force required to penetrate human skin (between 0.1 N and 3 N), 
indicating their suitability for use in vivo [61]. The MNs were examined under brightfield microscopy, 
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where it was found that the most common mode of failure was 90° deflection without breakage of the MN 
tip (Figure S3). 
After confirming that the PVP/PVA MNs possessed the required mechanical strength to breach the 
skin, their ability to release PEGylated dye within the skin was investigated, as rapid dissolution of the 
MNs in the skin is a desirable property for eventual clinical translations. Repeated applications of Cy7.5-
PEG MNs to mouse skin were performed to determine optimal application time; the minimum time 
required for release of the dye from the MN tips. After testing applications of 2, 5, and 8 minutes, it was 
found that there was no significant difference in the amount of dye delivered, suggesting that a 2 minute 
application was sufficient for full dissolution of the MN tips and delivery of the maximum possible 
amount of dye (Figure 2E). 
To validate the use of Cy7.5-PEG as an alternative to ICG, MNs were prepared with equivalent 
concentrations (720 µм) of either ICG or Cy7.5-PEG in the tips. After drying, the MN arrays were 
examined under fluorescence stereomicroscopy and the fluorescence intensities of individual MNs from 
each array were compared, with Cy7.5-PEG MNs displaying an average increase in fluorescence of 33 ± 5 
% relative to their ICG-containing counterparts (Figure 2F). This likely resulted from the partial 
degradation of ICG in the presence of PVP, as this polymer is known to contain reactive peroxide 
impurities [49]. In contrast, when MNs containing Cy7.5-PEG were stored for 30 days under ambient 
conditions, 87 ± 7 % of fluorescence was retained, indicating the stability of this formulation (Figure S4). 
MNs of each type were also applied to mouse skin, to compare the intensities of the resulting tattoos 
(Figure S5). In the skin, the average fluorescence intensity of a Cy7.5-PEG tattoo was found to be 126 ± 
41 % greater than the average signal of an ICG tattoo (Figure 2G). This was notable, as, when observed in 
aqueous solution, the fluorescence intensity of ICG was 22 ± 17 % greater than that of Cy7.5-PEG at the 
same concentration (Figure S6). The observed difference in fluorescence intensities could result from 
aggregation or quenching of ICG within the MNs and the skin, whereas Cy7.5-PEG appeared to exhibit 
greater solubility and stability in both environments [36,37]. For these reasons, in addition to the 
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improved lymphatic selectivity, Cy7.5-PEG was selected for subsequent in vivo studies. 
In addition to the stability of the fluorophore, the stability of the Cy7.5-PEG conjugate to 
hydrolysis was also investigated, to ensure that the dye remained PEGylated once delivered to the dermis. 
While the amide bond between PEG and the fluorophore is generally recognized as being stable in 
biological conditions, this had not previously been demonstrated for this specific conjugate [62,63]. To 
test this, Cy7.5-PEG was incubated in diluted fetal bovine serum (FBS) to mimic conditions found in the 
ISF of the dermis [64,65], and periodically monitored by LC-MS for the appearance of hydrolyzed free 
Cy7.5. Ultimately, it was found that the conjugate was fully stable for the first 6 hours of incubation, 
when drainage was expected to occur, with no hydrolysis observed during this time, indicating sufficient 
stability for subsequent in vivo studies. 
3.3. In vivo experiments in mice 
Following ex vivo optimization of dye delivery, tests were performed in vivo to determine 
whether MN-delivered Cy7.5-PEG could successfully be used to monitor lymphatic drainage in mice. To 
this end, MNs were applied to the shaved skin of mice for 3 minutes, and the resulting fluorescence signal 
was followed using an IVIS imaging system and a recently developed portable NIR fluorescence detector 
[49]. The signal was measured periodically over 24 h (Figure 3A), with a clear decrease in signal observed, 
following first-order decay kinetics, indicating that the dye was being drained from the application site. The 
signal initially displayed a steep decline, gradually leveling off into a plateau between T = 6 h and T = 24 h 
at 40 ± 10 % of the initial signal (IVIS) and 32 ± 11 % of the initial signal (portable device). Notably, the 
fluorescence signal also displayed no initial dequenching phase, as had previously been reported with ICG, 
likely due to the improved solubility of the PEGylated Cy7.5, as well as the tendency of ICG to display 
increased fluorescence intensity upon protein binding [28,38,41,49].  
To better quantify the drainage of Cy7.5-PEG, the relative fluorescence of each MN tattoo was 
plotted as a function of time and the area under the curve (AUC) was measured for each run (Figure 3B). 
This allowed comparison of the total amount of dye drained for each application, which could ultimately 
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be used to quantitatively differentiate between normal lymphatic drainage, and impaired lymphatic 
drainage in the context of diseases of the lymphatic system. Comparison of the fluorescence 
measurements collected by the IVIS and the portable fluorescence detector revealed that there was no 
significant difference between the drainage measured by either instrument (p ≤ 0.05), validating the use of 
the portable detector for this application (Figure 3C), which holds important implications for monitoring 
lymphatic drainage outside of a clinical setting [49].  
While the kinetics of Cy7.5-PEG drainage were found to be consistent between tests (± 10 %), 
the initial fluorescence intensity of the tattoos was found to vary more significantly, with the highest 
intensity application displaying 3.6-fold greater initial fluorescence than the lowest intensity application 
(Figures S7, S8). This was likely primarily due to variations in skin topography, particularly as the backs 
of mice acted as small and uneven surfaces for application. Notably, this supports the hypothesis that, due 
to the inherently relative nature of its quantification, the drainage behavior of the tattoo is independent of 
the amount of dye delivered (Figure S8). Finally, when comparing the half-life (t1/2) values 
(corresponding to the speed of drainage from the application site), a small difference was observed, with 
the portable device indicating shorter t1/2 values than the IVIS. However, this could be due to diffusion of 
the dye outside of the smaller field-of-view of the portable device during early stages of drainage, more 
rapidly lowering the observed fluorescence (Figure 3D). 
 
Figure 3. In vivo experiments in mice (IVIS vs portable device): A) Representative IVIS fluorescence 
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images of MN tattoo in mouse at t = 0, 1, 2, 4, 6, 24 h; B) Representative AUC plot of relative 
fluorescence intensity of Cy7.5-PEG in skin, measured using IVIS; C) Comparison between AUCs of 
measurements performed using IVIS and portable fluorescence detector; D) Comparison between half-
life values of Cy7.5-PEG drainage using IVIS and portable fluorescence detector. Mean ± SD (n = 7). 
3.4. In vivo experiments in rats 
Following initial results in mice, further in vivo studies were conducted in rats, a better model for 
human skin, owing to their similar skin thickness [66]. Specifically, the thickness of rat dorsal (back) skin 
was reported to be approximately 2 mm, which is comparable to or greater than many regions of the 
human body, including back, neck, and notably arm skin (a common location of lymphedema following 
breast cancer-associated axillary lymph node removal) [67]. Cy7.5-PEG-containing MNs of the same 
geometry and concentration used in mice were applied to the backs of shaved live rats (draining) for 3 
minutes, and the resulting fluorescence signal was measured periodically over 24 hours using an IVIS. As 
rat lymphedema models are complex, requiring microsurgery and/or irradiation to generate [68-70], and 
primarily affect the extremities — where reproducible MN application is impossible — MNs were also 
applied to the backs of shaved dead rats (non-draining) for the same amount of time, to act as negative 
controls displaying the absence of lymphatic drainage [68,71], to demonstrate the discrimination potential 
of the MN tattoo. Similar to mice, an initial steep decrease in signal was observed in living rats, with a 
plateau occurring between T = 6 h and T = 24 h (Figure 4A). However, this plateau occurred at a 
significantly higher fluorescence intensity than in mice, with 63 ± 8 % of the initial signal remaining after 
24 hours, suggesting that less Cy7.5-PEG was drained from the application site. This is likely due to the 
increased thickness of the non-viable epidermis in rats relative to mice, resulting in more dye remaining 
trapped in this non-drained region of the skin [66]. This was significantly different from the results 
observed in non-draining rats, where no drainage occurred, and the average T = 24 h fluorescence 
intensity corresponded to 85 ± 19 % of the initial signal (Figure 4A). The slight initial decrease in 
fluorescence observed could be attributed to passive diffusion of Cy7.5-PEG within the dermis, away 
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from the site of application, or minor changes in the position of the animal upon subsequent 
measurements. Additionally, the observation that minimal fluorescence is lost in the absence of lymphatic 
drainage suggests that minimal decay or degradation of the Cy7.5-PEG occurred over the measurement 
period.  
Upon comparison of the AUC values between draining (15.7 ± 0.7 RFU·h) and non-draining rats 
(21 ± 2 RFU·h), a significant difference was observed (p ≤ 0.05), suggesting that this MN tattoo is 
capable of discrimination between functional and non-functional lymphatic drainage (Figure 4B). The p-
value, corresponding to the statistical difference between the change in fluorescence in the presence or 
absence of lymphatic drainage, reflects the statistical power of the MN tattoo to discriminate between 
normal and impaired lymphatic drainage, with lower values indicating an increase in statistical 
significance. Histological examination of rat skin after MN application revealed significant Cy7.5-PEG 
fluorescence present in the outer epidermis, with no signal visible deeper in the dermis (Figures 4C, 4D). 
This further supports the notion that while dye delivered to the dermis or viable epidermis is readily 
drained through lymphatic vessels, any dye delivered to the outer epidermis remains trapped due to its 
size and hydrophilicity, resulting in the strong fluorescence after 24 hours [72,73]. 
 
 
Figure 4. In vivo MN applications in rats: A) Representative relative fluorescence decrease resulting 
from Cy7.5-PEG drainage in draining and non-draining rats; B) Comparison between AUCs of Cy7.5-
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PEG drainage curves in draining and non-draining rats. Mean ± SD (n = 6); C) Brightfield microscopy 
image of histology of rat skin after Cy7.5-PEG MNs1 application; D) Fluorescence microscopy image of 
histology of rat skin showing dye remaining trapped in outer epidermis (MNs were applied while rat was 
living). Scale bar = 1000 µm. 
3.5. Optimization of MN features for in vivo monitoring of lymphatic drainage 
To address the issue of dye remaining trapped in the outer epidermis, and potentially improve the 
discrimination potential of the system, the MN design was rationally optimized and tested. By modifying 
the MN preparation process, beginning with the solvent-casting method, the dye was specifically localized 
within the apex of the tips of the MNs for specific delivery to the deeper, lymphatically drained tissue, 
allowing greater drainage of the dye and thereby possibly improving the sensitivity of the MN tattoo. 
Specifically, when prepared using the standard method, the average height of dye within the MNs was 
measured as 368 ± 18 µm, corresponding to 75 % of the total length of the MNs (479 ± 13 µm) (MNs1, 
Figure 5A). When prepared using the modified method, Cy7.5-PEG was found to be present up to an 
average height of 286 ± 19 µm, or 60 % of the total MN length (MNs2, Figure 5A). Importantly, to 
evaluate the impact of delivery depth on the drainage of Cy7.5-PEG, longer MNs were prepared using 
molds with a nominal height of 800 µm (actual MN height measured as 651 ± 27 µm). When MNs of this 
length were prepared using the modified casting process, the presence of dye was observed up to a height 
of 304 ± 11 µm, only 45 % of the total MN length (MNs3, Figure 5A). This data was also reflected in ex 
vivo MN insertion tests in excised skin. Histological examination showed that MNs1 and MNs2 delivered 
Cy7.5-PEG to average depths of 236 ± 69 µm and 243 ± 41 µm respectively, while the longer MNs3 




Figure 5: Structure and delivery comparison of MNs1, MNs2, and MNs3: A) Relative heights and 
location of dye within MNs1, MNs2, and MNs3. Mean ± SD (n = 10); B) Average depth of Cy7.5-PEG 
delivery in porcine skin for MNs1, MNs2 and MNs3. Mean ± SD (n = 20).  
These modified MNs were also tested in vivo in draining rats, and the decrease in fluorescence 
was monitored by IVIS, as previously described. For the MNs2, drainage appeared very similar to 
previous tests, with an initial decline followed by a slow plateau to 61 ± 7 % of initial fluorescence. For 
the MNs3, however, improved drainage was observed, gradually reaching an average T = 24 h 
fluorescence signal of 50 ± 7 % of the initial signal, lower than previously observed (Figure 6B). Both 
types of MNs were also applied to non-draining rats, yielding results similar to previous tests (84 ± 9 % 
for MNs2, 91 ± 22 % for MNs3), with no drainage observed after 24 hours (Figure 6C). Interestingly, the 
variability of the amount of dye delivered by each class of MNs was similar (Figure S10), further 
supporting the notion that the rate of drainage does not vary depending on the total amount of dye 
delivered to the skin.   
After application of both MNs2 and MNs3, the AUCs were compared for each MN type, to 
quantitatively assess their performance. Initially, half-life (t1/2) was also considered for comparison 
between the different classes of MNs (MNs1, MNs2, MNs3), but it was determined to be poor fit for this. 
This is because, while t1/2 is well-suited for comparing rates of lymphatic drainage, it cannot be 
determined in non-draining rats, as their absence of lymphatic drainage prevents the exponential curve-
fitting required for half-life determination (Figure S11). The difference between the MN classes is 
17 
 
instead related to the total amount of dye drained, which is expressed as the area under the curve (AUC). 
Since the MNs were compared in healthy animals, which should display similar rates of lymphatic 
drainage, the half-life of the PEGylated conjugate should remain the same, regardless of the class of MNs 
used to deliver it. However, when comparing the AUCs, a difference was expected, as the different 
classes of MNs delivered different amounts of dye to the dermis, depending on their length and the 
location of the dye. 
For MNs2, AUCs were very similar to those previously observed, with 15.6 ± 0.6 RFU·h for 
draining rats and 21.0 ± 0.9 RFU·h for non-draining rats, though the difference was found to be more 
significant (p ≤ 0.0005) due to less signal variability between applications (Figure 6D). For the MNs3, the 
difference was more pronounced, with the average AUC in draining rats measured as 13.7 ± 0.4 RFU·h, 
compared to 23 ± 2 RFU·h in non-draining rats (Figure 6F). The significance of this difference  (p < 
0.0001) was greater than any previously observed, and — coupled with the overall greater drainage 
observed— suggests that the length of the MNs has an impact on the discrimination potential of the 
tattoo, likely owing to the presence of less dye in the outer epidermis (Table 1). This was further 
supported by comparison between the average AUCs of each class of MNs. It was found that the average 
AUC in draining rats for MNs1 (15.7 ± 0.7 RFU·h) was significantly different (p ≤ 0.05) from MNs3 
(13.7 ± 0.4 RFU·h), but not from MNs2 (15.6 ± 0.6 RFU·h), highlighting the improved lymphatic 
drainage afforded by the optimized MN design. 
Additionally, the different classes of MNs were directly compared by considering the relative 
increase in drainage provided by each class of MNs in draining vs. non-draining rats. This involved 
normalizing the average AUC from each class of MNs against the mean AUC in non-draining rats to 
obtain the fold-increase in drainage provided by each class of MNs. In doing so, MNs1 were determined 
to provide a 1.39 ± 0.14-fold increase in draining relative to non-draining animals, while MNs2 and 
MNs3 provided 1.40 ± 0.12-fold and 1.59 ± 0.16-fold increases respectively (Table 1). This constituted a 
significant difference (p ≤ 0.05) between MNs1 and MNs3, indicating that the optimized design of MNs3 
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provided the best resolution of drainage vs. absence of drainage among the MN designs studied.  
 
Figure 6. Optimization of MNs for in vivo tests: A) Fluorescence microscopy images of (top to bottom) 
MNs2, and MNs3; B) AUC plot of relative fluorescence decrease in draining rats of Cy7.5-PEG delivered 
using MNs3. Mean ± SD (n = 9); C) AUC plot of fluorescence in non-draining rats of Cy7.5-PEG 
delivered using MNs3. Mean ± SD (n = 6); D) Comparison between AUCs of Cy7.5-PEG drainage curves 
in draining and non-draining rats using MNs2. Mean ± SD (n = 6); E) Comparison between AUCs of 




Table 1. Overall properties and in vivo drainage data of different classes of MNs in rats. (*) denotes significance of 
difference between draining and non-draining rats detectable with each class of MNs; (*) p ≤ 0.05; (***) p ≤ 
0.0005; (****) p < 0.0001. (+) denotes significance of difference in performance between each class of MNs; (+) p 
≤ 0.05. 
 





Loading [µm] Depth [µm] Remaining 





MNs1 479 ± 13 368 ± 18 (76.8 %) 236 ± 69 63 ± 8% 
15.7 ± 0.7 
(*) 
21 ± 2 1.39 ± 0.14 
MNs2 479 ± 13 286 ± 19 (59.8 %) 243 ± 41 61 ± 7 % 
15.6 ± 0.6 
(***) 
21.0 ± 0.9 1.40 ± 0.12 
MNs3 651 ± 27 304 ± 11 (46.7 %) 329 ± 44 50 ± 7% 
13.7 ± 0.4 
(****)(+) 
23 ± 2 1.59 ± 0.16 
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4. Conclusions & Outlook 
Due to the growing recognition of the importance of the lymphatic vascular system in various 
diseases, the evaluation and monitoring of its function has rapidly gained interest in the scientific and 
medical community. In light of this, the system developed in this study represents a step towards a 
viable MN-based method of lymphatic monitoring. By delivering a PEGylated NIR dye highly selective 
for lymphatic drainage, we were able to create a MN tattoo capable of discriminating between 
lymphatic drainage and the absence of lymphatic drainage in vivo in rats. Through rational optimization 
of the MN structure, it was determined that the length of the MNs appears to be the most important 
parameter governing the diagnostic potential of this procedure, owing to the effect on the delivery depth 
of the dye. In doing so, we identified important parameters for dissolving polymeric MN-based 
delivery, with great potential significance for future clinical translations of this technology, as well as 
generally for the delivery of drugs and diagnostic agents with dissolving polymeric MNs. Moreover, it 
was demonstrated, for the first time, that the lymphatic drainage of a MN tattoo could be measured 
using a portable fluorescence detector, which constitutes an important clinical advantage for NIR 
fluorescence imaging of lymphatic drainage, opening the door to at-home and point-of-care monitoring 
without the need for bulky and expensive detection equipment and trained personnel. Performing this 
analysis in a minimally invasive manner at home would therefore help improve quality of life for 
lymphedema patients requiring regular monitoring of lymphatic drainage and allow more rapid 
detection of changes in health status. Notably, this study also revealed that when delivered using 
dissolving polymeric MNs, a portion of the PEGylated dye remains in the stratum corneum and is 
minimally drained — an important consideration for future studies of this class of MNs for drug 
delivery applications. Finally, while it was demonstrated that the MN tattoo could readily discriminate 
between drainage vs absence of drainage, this discrimination potential remains to be assessed in clinical 
settings. In particular, optimal MN length and dye location would need to be evaluated in humans, in 
order to identify the most sensitive diagnostic procedure. Such studies would be of particular 
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importance, given the clinical presentation of lymphedema in humans, which can involve thickening of 
the skin [74,75]. While studies have shown that this thickening is primarily localized to the 
lymphatically vascularized dermis, rather than the stratum corneum, where dye could remain trapped, 
this symptom should nonetheless be taken into consideration [74]. It is worth noting, however, that such 
skin thickening tends to be observed alongside other symptoms (such as visible swelling) during later 
stages of lymphedema, past the early-detection stage where the MN tattoo would be most useful [76].  
This would reveal whether the discrimination potential is sufficient to detect and quantify lymphedema, 
as well as other diseases related to impairment of lymphatic drainage.  
5. Experimental 
5.1. Materials 
Poly(N-vinylpyrrolidone) (3.5 – 7 kDa) (PVP K-12) was kindly provided by BASF 
(Ludwigshafen, Germany). Poly(vinyl alcohol) (10 kDa) (PVA) and fetal bovine serum (FBS) were 
purchased from Sigma-Aldrich (St. Louis, MO). Indocyanine green (ICG, IR125, laser grade) and 
dimethyl sulfoxide (DMSO) were purchased from Acros Organics (Morris Plains, NJ). Cyanine 7.5 
NHS ester (Cy7.5-NHS) was purchased from Lumiprobe (Hunt Valley, MD). Methoxy-poly(ethylene 
glycol) amine (MeO-PEG-NH2) (20 kDa) was purchased from JenKem Technologies (Plano, TX). 
Sephadex G-15 was purchased from GE Life Sciences (Mississauga, ON). Square pyramidal female 
MN molds made of room temperature vulcanizing silicone, 10 × 10 array, 250 µm × 250 µm × 800 µm 
(W × L × H) and 15 × 15 array, 250 µm × 250 µm × 600 µm (W × L × H) with peak-to-peak spacing of 
500 µm were purchased from Micropoint Technologies Pte. Ltd. (Singapore). 
5.2. Synthesis of Cy7.5-PEG 
Cy7.5-PEG was synthesized by adapting a previously described procedure [41]. Briefly, Cy7.5-
NHS (6.0 mg, 7.2 µmol, 1 eq) and MeO-PEG-NH2 (MW = 20,000 g/mol) (144 mg, 7.2 µmol, 1 eq) were 
dissolved in anhydrous DMSO (2 mL), and the mixture was stirred in the dark for 18 – 24 h. Following 
this, the mixture was diluted in milli-Q H2O (40 mL) and lyophilized. The resulting residue was 
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dissolved in 180 mм NaCl (1 mL) and purified on G-15 Sephadex. The fractions were combined and 
lyophilized, yielding Cy7.5-PEG as a light green solid (95 mg, 4.5 µmol, 63% yield). The purity of the 
product was confirmed by HPLC-MS analysis (Figure S12). 
5.3. Stability of Cy7.5-PEG 
The stability of the Cy7.5-PEG conjugate to hydrolysis was evaluated in FBS diluted to 
simulate the protein concentration of ISF [64,65]. Briefly, Cy7.5-PEG was dissolved in FBS diluted to 
20.6 g/L and stored in the dark for 6 h. Periodically, samples were analyzed by HPLC-MS for 
appearance of a free Cy7.5 peak, indicating hydrolysis.   
5.4. Preparation of Cy7.5-PEG-loaded MNs 
MNs were manufactured by adapting a previously described solvent casting method (Figure 
S13) [49]. Briefly, to distilled H2O (2 mL), PVP K-12 (0.800 g) and PVA (0.800 g) were added and 
mixed thoroughly. The mixture was heated for 30 – 40 mins in a 75 °C oven and centrifuged (Sorvall 
ST 16R, ThermoFisher Scientific, Waltham, MA) for 5 mins at 4700 g, generating a polymer matrix 
solution (PMS). For the tips, Cy7.5-PEG was added to the matrix solution, resulting in a final 
concentration of 720 µм (PMS1), while for the backing layer, no dye was added (PMS2). Using a 1 mL 
syringe, roughly 100 µL of PMS1 was cast into PDMS molds (Micropoint Technologies Pte. Ltd., 
Singapore) and these molds were secured with tape in 6-well cell culture plates (Sarstedt AG & Co., 
Nümbrecht, Germany). The plates were covered, secured with parafilm, and centrifuged for 5 mins at 
2300 g. After centrifugation, PMS1 was re-applied, and the plates were rotated 180° and centrifuged 
again. This process was repeated a total of four times. After the final centrifugation, any excess PMS1 
was removed from the molds using a spatula, and they were placed in a vacuum chamber at 150 mbar 
for 30 minutes. One hundred µL of PMS2 was added to each mold, and they were allowed to dry for 18 
– 24 h at 25 °C and 60% humidity, after which the MNs were removed from the molds. For the 
modified solvent-casting procedure (Figure 5), after removal of excess PMS1 from the molds, a spatula 
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was scraped along the bottom of the molds to further remove PMS1 from the MN tips. This was 
followed by a fifth and final centrifugation using PMS2 to fill the resulting space, vacuum drying at 150 
mbar for 30 minutes, and application of a PMS2 backing layer. 
5.5. Characterization of mechanical properties of MNs 
The failure force of the MNs was evaluated using a TA.XT-Plus Texture Analyzer (Stable 
Micro Systems, Surrey, UK) in compression mode. MNs were prepared as previously described, without 
addition of dye, and with or without addition of PEG-NH2 (20 kDa). MNs were placed on an aluminum 
plate and a cylindrical stainless-steel probe (6 mm diameter) was moved towards the MNs. The probe 
moved at 1.2 mm·s-1 with a maximum travel distance of 300 µm (sufficient to induce MN deflection). 
The MN failure force was measured as the maximum of the force-time curve [77]. 
5.6. Application of Cy7.5-PEG MNs in vivo in mice 
Animals 
Mice were kept under specific pathogen–free conditions until imaging. FVB mice were bred in- 
house at the EPIC animal facility at ETH Zürich. All mouse experiments were carried out in strict 
accordance with an animal protocol approved by the Cantonal Veterinary Office, Zürich, Switzerland 
(protocol number: ZH212/16). 
In vivo imaging 
The IVIS Spectrum imaging system and the custom portable device were used simultaneously 
for the in vivo clearance assay in the back skin of mice [49]. Six 19-week-old male FVB mice were 
used for the assay. Mice were anesthetized with 2% isoflurane, and fur was removed from the back skin 
in an area of approximately 3 cm in diameter using an electric shaver followed by depilating cream 
(Nair, Church & Dwight, Ewing, NJ). MNs were applied under anesthesia using a commercially 
available spring-loaded applicator generating an impact rate of 2 m·s-1, an impact force of 1.6 N, and 
with a spring constant of 1 N·mm-1 (values provided by the manufacturer, Micropoint Technologies Pte. 
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Ltd., Singapore) with prolonged contact for 3 minutes for each application. Animals were imaged in an 
IVIS Spectrum (Caliper Sciences, Hopkinton, MA) in fluorescence mode using a field of view of 6.6 cm 
× 6.6 cm (FOV D) with an exposure time of 1.5 seconds, lens aperture (fstop) of f/16 and pixel binning 
set to 8. The excitation lamp was set to high intensity with the 745 nm excitation filter and the ICG 
emission filter (810 – 875 nm). The average fluorescence intensity in a circular ROI (3 cm in diameter) 
was analyzed using Living Image Software. Simultaneously, measurements were performed with the 
custom portable NIR fluorescence detector. After tracer injection, the circular area (3 cm in diameter) 
around the application site was marked. The device was moved slightly around the marked injection area 
until the region of highest intensity was detected. Six measurements were then recorded, and the average 
of the 3 highest values were used for the data analysis. After subtracting the background readout, the 
values obtained by each instrument were normalized to the time 0 measurement and plotted against time. 
Animals recovered normally from anesthesia, and displayed no signs of pain or discomfort following 
MN application. 
5.7. Application of Cy7.5-PEG MNs in vivo in rats 
Animals 
Female Sprague-Dawley rats (Charles River, Senneville, QC) with weights ranging from 400 – 
500 g were fed with Alfalfa-free rodent diet (Envigo RMS Inc., Lachine, QC) for 3 weeks prior to 
experimentation. Experiments were conducted under an ethical protocol approved by the Animal Care 
Committee of the Faculty of Pharmacy at the University of Montreal (protocol: 19-002) and the Animal 
Care Council from the Cégep de Lévis-Lauzon (protocol: 002-19). 
In vivo imaging 
Rat dorsal skin was shaved and depilated under 2% isoflurane-induced anesthesia using an 
electric razor and depilating cream (Nair, Church & Dwight, Ewing, NJ) the day before experimentation. 
For studies in dead animals, rats were euthanized under anesthesia by cervical dislocation using cutting 
pliers. Carcasses were kept away from light between scans and kept at 4 °C for the overnight incubation. 
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For living animals, MNs were applied under anesthesia using a commercially available spring-loaded 
applicator, with a prolonged contact for 3 minutes for each application. Animals were kept away from 
direct light between imaging sessions. 
Animals were imaged in an IVIS Lumina XR (Caliper Sciences, Hopkinton, MA) in 
fluorescence mode using a field of view of 12.5 cm × 12.5 cm (FOV D) with exposure time set to auto-
compensated, lens aperture (fstop) of f/16 and pixel binning set to 8. The excitation lamp was set to high 
with the 745 nm excitation filter and the ICG emission filter (810 – 875 nm). Quantitative data were 
obtained by drawing square (with constant area) regions of interest (ROIs) around the MN application 
site to measure fluorescence efficiencies (in %) which correspond to the quotient of emitted light 
divided by the excitation light (both in photons/second). After subtracting the background readout, the 
values obtained were normalized to the time 0 measurement and plotted against time. Areas under the 
curve (AUCs) were calculated using GraphPad Prism 7 (San Diego, CA). Animals recovered normally 
from anesthesia, and displayed no signs of pain or discomfort following MN application. 
5.8. Histological Analysis 
The skin area was harvested and frozen at -80 °C in Optimal Cutting Temperature (OCT)-
sucrose compound. Sections of 50 µm were cut, chilled by dry ice, and stored at -80 °C until imaging 
for Cy7.5 signal with a fluorescence stereomicroscope (AxioZoom.V16, Zeiss, Oberkochen, Germany) 
equipped with NIR settings (Excelitas Technologies X-Cite® Xylis light source; Photometrics® Prime™ 
95B camera) using a Cy7 long pass filter set (λex = 675 nm, λem ≥ 730 nm). Sections were then stained 
with hematoxylin and eosin, and the same regions were imaged under white light excitation (exposure 
time: 75 and 100 ms for mouse and rat skin, respectively). 
5.9. Statistical Analysis 
Mean and standard deviation are reported for all data. Significance was analyzed using the 
Mann-Whitney non-parametric t-test (p-value < 0.05) for comparisons between two datasets (see 
Figures 2, 3, 4, and 6), or one-way ANOVA (p-value < 0.05) for comparisons between multiple 
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datasets (see Figure 5b and Table 1) with Tukey’s HSD post hoc test to correct for multiple 
comparisons. Bartlett’s test was used to confirm homogeneity of variance, and the Shapiro-Wilk 
normality test was used to confirm normality of distribution. All graphs were plotted using GraphPad 
Prism 7 (San Diego, CA). Statistical significance denoted using *, where (*) p ≤ 0.05; (**) p ≤ 0.005; 
(***) p ≤ 0.0005; (****) p < 0.0001.  
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Table 1. Overall properties and in vivo drainage data of different classes of MNs in rats. (*) 
denotes significance of difference between draining and non-draining rats detectable with each 
class of MNs; (*) p ≤ 0.05; (***) p ≤ 0.0005; (****) p < 0.0001. (+) denotes significance of 




















MNs1 479 ± 13 
368 ± 18 
(76.8 %) 
236 ± 69 63 ± 8% 
15.7 ± 0.7 
(*) 
21 ± 2 1.39 ± 0.14 
MNs2 479 ± 13 
286 ± 19 
(59.8 %) 
243 ± 41 61 ± 7 % 
15.6 ± 0.6 
(***) 
21.0 ± 0.9 1.40 ± 0.12 
MNs3 651 ± 27 
304 ± 11 
(46.7 %) 
329 ± 44 50 ± 7% 
13.7 ± 0.4 
(****)(+) 
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